Overview

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Status:
Active, not recruiting

Trial end date:
2023-09-30

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women with breast cancer. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Anastrozole
Aromatase Inhibitors
Letrozole